Trial Profile
A parallel group randomised, controlled, multi-centre phase II open label trial to evaluate progression free survival in Cohort A: Pancreatic NETs - peptide receptor radionuclide therapy (PRRT)/capecitabine + temozolomide (CAPTEM) vs. CAPTEM (control) and Cohort B: Midgut NETs - PRRT/CAPTEM vs. PRRT (control)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Capecitabine; Temozolomide
- Indications Intestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CONTROL NETS
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 09 Mar 2022 Status changed from active, no longer recruiting to completed.
- 31 May 2020 First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS) from this study, were presented at the 56th Annual Meeting of the American Society of Clinical Oncology.